Furiex Pharmaceuticals Inc (FURX)

[surf1944]

Furiex Pharmaceuticals, Inc. (FURX) is a drug development collaboration company. The current market price is $15.52 with a one-year analyst price target of $25. This represents a 61.08% upside potential. I love that Furiex is a cash-rich company, with a total cash position on its balance sheet of $54.81 million and total debt of zero. The company has been gaining a lot of momentum recently, due in part to the heavy insider buying. Director Fredric N. Eshelman bought 265,017 shares or $4.2 Million, at $15.97 per share. Mr. Eshelman increased his stake by 19.69% to 1,611,220 shares with this purchase. Also, Chief Financial Officer Marshall H. Woodworth acquired 6,211 shares or $91,799 at $14.78 per share. The large acquisition by key insiders signals a strong buy. It seems they are aware of something that might not yet be reflected in the market price.

http://seekingalpha.com/article/309827-eye-on-these-4-stocks-with-heavy-insider-trading?source=yahoo